Pacific Edge’s share price boosts after critical panel meeting

Shares in NZX and ASX-listed cancer diagnostics company Pacific Edge have risen more than 20% in early trading following a Contractor Advisor Committee meeting in the US regarding the use of urine-based biomarker test in the evaluation of haematuria.

Trading in the company’s shares resumed today

Want to read more? It's easy.

Choose your subscription

Already have an account? Login

Smartphone Only Subscription

NZ$29.95 / monthly

Monthly Premium Online Subscription

NZ$49.95 / monthly

Smartphone Only Annual Subscription

NZ$299.00 / yearly

Yearly Premium Online Subscription

NZ$499.00 / yearly

Premium Group Membership 10 Users

NZ$385+GST / monthly

$38.5 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$660+GST / monthly

$33 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1375+GST / monthly

$27.5 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$2100+GST / monthly

$21 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$999.00 / yearly

Individual

Group membership

NBR Marketplace

Student

Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).

View terms and conditions.

Fiona Rotherham Mon, 23 Feb 2026

Contact the Writer: fiona@nbr.co.nz

News tip? Question? Typo? Let us know: editor@nbr.co.nz

Categories

Analysis

Featured